Sarmen Sarkissian, MD Durvalumab is an FFP—L1 monoclonal antibody that has been approved and metastatic or unresectable urothelial carcinoma. It has also been approved in the adjuvant setting for nonresectable non-small cell lung cancer. It phase I—phase II clinical trial of locally advanced or metastatic urothelial carcinoma, Dr Powles reported in JAMA Oncology, on 191 patients. Patients are treated with the antibody at 10 mg/kg. He was administered every 2 weeks for up to 12 months or until disease progression. Patient’s either refusal was not eligible for first line chemotherapy. Median age was 67 years old. 71% of patients will none. All had stage IV disease. 99% had prior treatment. At a median follow-up of 6 months, the objective response rate 70.8%. Complete responses were seen in 7 patients. Median time to response was nearly 1-1/2 months. Median duration of response was not reached with more than 17 patient’s sustaining a response greater than 6 months. 77% of responders have an ongoing response at the clinical. Only 7% of patients had grade 3 or 4-related toxicity.
https://jamanetwork.com/journals/jamaoncology/article-abstract/2648865?redirect=true
https://jamanetwork.com/journals/jamaoncology/article-abstract/2648865?redirect=true
RSS Feed